For the quarter ended June 2024, Amneal Pharmaceuticals (AMRX) reported revenue of $701.78 million, up 17.2% over the same period last year. EPS came in at $0.16, compared to $0.19 in the year-ago quarter.The reported revenue represents a surprise of +6.75% over the Zacks Consensus Estimate of $657.43 million. With the consensus EPS estimate being $0.14, the EPS surprise was +14.29%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wa ...

Have you been paying attention to shares of Amneal Pharmaceuticals (AMRX) ? Shares have been on the move with the stock up 7.2% over the past month. The stock hit a new 52-week high of $7.81 in the previous session. Amneal Pharmaceuticals has gained 28% since the start of the year compared to the 6.6% move for the Zacks Medical sector and the -2.9% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.09 per share when it actually produced earnings of $0.14, delivering a surprise of 55.56%.Over the last four ...

Exhibit 99.2 AMNEAL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS ‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT U.S. FDA approval represents an exciting new long-term growth driver ‒ ® BRIDGEWATER, NJ, August 9, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") announced its results today for the second quart ...

Wall Street analysts forecast that Amneal Pharmaceuticals (AMRX) will report quarterly earnings of $0.14 per share in its upcoming release, pointing to a year-over-year decline of 26.3%. It is anticipated that revenues will amount to $657.43 million, exhibiting an increase of 9.8% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 4.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated t ...

The market expects Amneal Pharmaceuticals (AMRX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 9, 2024, might help the stock move higher if these key numb ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Amneal Pharmaceuticals is one of 1024 companies in the Medical group. The ...

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, invest ...

Paul Bradbury/OJO Images via Getty Images Investment Overview This is my third note for Seeking Alpha covering Amneal Pharmaceuticals (NASDAQ:AMRX), the "global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals", according to its 2023 annual report / 10K submission. In March 2022, I gave Amneal stock a "Buy" recommendation after its share price ...